Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$73.50 -0.4%	$73.69	$62.75 ▼ $87.68	$227.94B	0.41	5.09 million shs	3.89 million shs
CME CME Group	$265.29 +1.2%	$250.30	$190.70 ▼ $267.91	$95.60B	0.53	2.04 million shs	2.41 million shs
LLY Eli Lilly and Company	$825.42 +0.4%	$846.30	$711.40 ▼ $972.53	$779.88B	0.34	3.30 million shs	3.74 million shs
MS Morgan Stanley	$116.85 +1.3%	$129.19	$85.01 ▼ $142.03	$188.45B	1.35	6.51 million shs	7.62 million shs
NVDA NVIDIA	$108.38 -1.2%	$124.42	$75.61 ▼ $195.95	$2.64T	1.77	313.41 million shs	298.47 million shs
PFE Pfizer	$25.36 +0.6%	$26.05	$24.48 ▼ $31.54	$143.80B	0.61	38.94 million shs	53.46 million shs
WFC Wells Fargo & Company	$71.85 +1.6%	$75.73	$50.15 ▼ $81.50	$234.59B	1.16	17.06 million shs	14.85 million shs
XLP Consumer Staples Select Sector SPDR Fund	$81.67 +1.6%	$80.42	$72.93 ▼ $84.53	$16.63B	0.58	10.92 million shs	14.29 million shs
XLV Health Care Select Sector SPDR Fund	$146.01 +1.0%	$146.45	$135.95 ▼ $159.64	$38.54B	0.68	7.48 million shs	8.09 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-0.39%	-0.80%	-3.56%	+12.18%	+8.49%
CME CME Group	+1.17%	+0.89%	+4.54%	+14.24%	+23.22%
LLY Eli Lilly and Company	+0.62%	-4.68%	-10.32%	+6.92%	+6.10%
MS Morgan Stanley	+1.40%	-6.06%	-12.22%	-7.06%	+24.09%
NVDA NVIDIA	-1.18%	-10.73%	-13.16%	-19.29%	+19.95%
PFE Pfizer	+0.61%	-2.98%	-4.07%	-4.43%	-8.63%
WFC Wells Fargo & Company	+1.61%	-3.28%	-8.30%	+2.29%	+23.96%
XLP Consumer Staples Select Sector SPDR Fund	+1.57%	+2.86%	-1.70%	+3.89%	+6.95%
XLV Health Care Select Sector SPDR Fund	+1.03%	-0.77%	-1.96%	+6.14%	-1.16%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.9836 of 5 stars	2.6	5.0	1.7	0.0	3.6	0.0	1.3
CME CME Group	4.0482 of 5 stars	2.0	3.0	2.5	2.9	3.5	3.3	0.6
LLY Eli Lilly and Company	4.8016 of 5 stars	2.4	5.0	3.3	4.0	3.4	2.5	1.9
MS Morgan Stanley	4.8531 of 5 stars	3.2	3.0	4.2	2.4	3.5	2.5	2.5
NVDA NVIDIA	4.8899 of 5 stars	4.5	3.0	1.7	3.0	3.3	2.5	1.9
PFE Pfizer	4.9816 of 5 stars	3.3	3.0	4.2	4.2	2.7	3.3	3.1
WFC Wells Fargo & Company	4.5487 of 5 stars	2.3	3.0	2.5	2.5	3.5	1.7	3.1
XLP Consumer Staples Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$89.75	22.11% Upside
CME CME Group	2.06	Hold	$238.93	-9.94% Downside
LLY Eli Lilly and Company	2.85	Moderate Buy	$1,009.72	22.33% Upside
MS Morgan Stanley	2.33	Hold	$131.53	12.57% Upside
NVDA NVIDIA	2.98	Moderate Buy	$171.51	58.25% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	25.90% Upside
WFC Wells Fargo & Company	2.58	Moderate Buy	$74.97	4.35% Upside
XLP Consumer Staples Select Sector SPDR Fund	2.53	Moderate Buy	$81.67	N/A
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$146.01	N/A

Current Analyst Ratings Breakdown

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	MS Morgan Stanley	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$142.00 ➝ $130.00
3/25/2025	MS Morgan Stanley	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$124.00 ➝ $129.00
3/24/2025	MS Morgan Stanley	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$135.00 ➝ $125.00
3/24/2025	WFC Wells Fargo & Company	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$82.00 ➝ $78.00
3/20/2025	NVDA NVIDIA	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$135.00 ➝ $125.00
3/20/2025	NVDA NVIDIA	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/19/2025	NVDA NVIDIA	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$190.00
3/19/2025	NVDA NVIDIA	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$162.00
3/19/2025	NVDA NVIDIA	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$180.00
3/19/2025	MS Morgan Stanley	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$144.00 ➝ $126.00
3/19/2025	NVDA NVIDIA	Susquehanna Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$180.00 ➝ $180.00

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.22	$6.23 per share	11.79	$13.18 per share	5.58
CME CME Group	$6.13B	15.60	$12.09 per share	21.95	$73.50 per share	3.61
LLY Eli Lilly and Company	$45.04B	17.38	$13.46 per share	61.34	$15.05 per share	54.85
MS Morgan Stanley	$57.62B	3.27	$7.32 per share	15.97	$55.58 per share	2.10
NVDA NVIDIA	$130.50B	20.26	$0.96 per share	112.93	$1.72 per share	63.01
PFE Pfizer	$63.63B	2.26	$3.97 per share	6.38	$15.81 per share	1.60
WFC Wells Fargo & Company	$82.30B	2.85	$6.71 per share	10.70	$48.79 per share	1.47
XLP Consumer Staples Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	32.52	14.70	1.42	13.01%	32.23%	12.31%	4/24/2025 (Estimated)
CME CME Group	$3.53B	$9.67	27.43	24.14	6.76	57.52%	13.62%	2.81%	4/23/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	70.49	26.52	1.40	23.51%	85.24%	16.19%	5/1/2025 (Estimated)
MS Morgan Stanley	$13.39B	$7.94	14.72	12.39	1.18	12.48%	14.39%	1.09%	4/15/2025 (Estimated)
NVDA NVIDIA	$29.76B	$2.94	42.65	27.23	1.76	55.69%	114.83%	76.61%	5/28/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.98	8.37	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
WFC Wells Fargo & Company	$19.72B	$5.38	13.35	10.46	1.18	15.73%	12.38%	1.04%	4/11/2025 (Estimated)
XLP Consumer Staples Select Sector SPDR Fund	N/A	N/A	21.99	∞	N/A	N/A	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.25	∞	N/A	N/A	N/A	N/A	N/A

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	AZN AstraZeneca	$1.10	N/A	N/A	N/A	N/A	N/A
4/23/2025	N/A	CME CME Group	$2.61	N/A	N/A	N/A	$1.56 billion	N/A
4/15/2025	N/A	MS Morgan Stanley	$2.22	N/A	N/A	N/A	$16.81 billion	N/A
4/11/2025	N/A	WFC Wells Fargo & Company	$1.24	N/A	N/A	N/A	$20.82 billion	N/A
2/26/2025	Q4 2025	NVDA NVIDIA	$0.84	$0.89	+$0.05	$0.89	$38.16 billion	$39.33 billion
2/12/2025	Q4 2024	CME CME Group	$2.46	$2.52	+$0.06	$2.40	$1.51 billion	N/A
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/16/2025	Q4 24	MS Morgan Stanley	$1.54	$2.22	+$0.68	$2.22	$15.03 billion	$16.23 billion
1/15/2025	Q4 2024	WFC Wells Fargo & Company	$1.34	$1.43	+$0.09	$1.43	$20.58 billion	$20.38 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.80%	+1.98%	91.15%	N/A
CME CME Group	$5.00	1.88%	+42.42%	51.71%	N/A
LLY Eli Lilly and Company	$6.00	0.73%	+15.21%	51.24%	11 Years
MS Morgan Stanley	$3.70	3.17%	+19.13%	46.60%	12 Years
NVDA NVIDIA	$0.04	0.04%	+33.42%	1.36%	N/A
PFE Pfizer	$1.72	6.78%	+2.50%	121.99%	16 Years
WFC Wells Fargo & Company	$1.60	2.23%	+35.72%	29.74%	N/A
XLP Consumer Staples Select Sector SPDR Fund	$2.18	2.67%	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	$2.29	1.57%	N/A	N/A	N/A

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/26/2025	NVDA NVIDIA	quarterly	$0.01	0.03%	3/12/2025	3/12/2025	4/2/2025
2/6/2025	CME CME Group	quarterly	$1.25	2.07%	3/7/2025	3/7/2025	3/26/2025
1/9/2025	XLP Consumer Staples Select Sector SPDR Fund		$0.4182		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLP Consumer Staples Select Sector SPDR Fund		$0.4182		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025
1/28/2025	WFC Wells Fargo & Company	quarterly	$0.40	2.05%	2/7/2025	1/7/2025	3/1/2025
1/16/2025	MS Morgan Stanley	quarterly	$0.9250	2.82%	1/31/2025	1/31/2025	2/14/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
CME CME Group	0.10	1.01	1.02
LLY Eli Lilly and Company	2.00	1.15	0.97
MS Morgan Stanley	3.14	0.80	0.80
NVDA NVIDIA	0.13	4.10	3.64
PFE Pfizer	0.63	1.00	0.73
WFC Wells Fargo & Company	1.07	0.86	0.85
XLP Consumer Staples Select Sector SPDR Fund	N/A	N/A	N/A
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
CME CME Group	87.75%
LLY Eli Lilly and Company	82.53%
MS Morgan Stanley	84.19%
NVDA NVIDIA	65.27%
PFE Pfizer	68.36%
WFC Wells Fargo & Company	75.90%
XLP Consumer Staples Select Sector SPDR Fund	N/A
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
CME CME Group	0.30%
LLY Eli Lilly and Company	0.13%
MS Morgan Stanley	0.24%
NVDA NVIDIA	4.23%
PFE Pfizer	0.06%
WFC Wells Fargo & Company	0.08%
XLP Consumer Staples Select Sector SPDR Fund	N/A
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
CME CME Group	3,460	360.36 million	359.28 million	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
MS Morgan Stanley	82,400	1.61 billion	1.61 billion	Optionable
NVDA NVIDIA	26,200	24.40 billion	23.45 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
WFC Wells Fargo & Company	238,000	3.27 billion	3.33 billion	Optionable
XLP Consumer Staples Select Sector SPDR Fund	N/A	203.62 million	N/A	Not Optionable
XLV Health Care Select Sector SPDR Fund	N/A	263.97 million	N/A	Not Optionable

PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Headlines

Recent News About These Companies

Waters Corporation Stock: Is WAT Outperforming the Healthcare Sector?

March 26, 2025 | msn.com

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

March 26, 2025 | americanbankingnews.com

S&P sector rankings as the first quarter of 2025's close is around the corner

March 24, 2025 | msn.com

3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs Data

March 14, 2025 | zacks.com

Merck and 8 More Healthcare Stocks for Nervous Dividend Investors

March 13, 2025 | msn.com

Select Sector SPDR ETFs: Strategic Investment with Sector-Specific Allocations

March 12, 2025 | finance.yahoo.com

Recession Fears Looming? Secure Your Portfolio With These ETFs

March 11, 2025 | zacks.com

Health Care Sector Trying to Bounce Back

March 6, 2025 | theglobeandmail.com

Shifting Tides in Leadership: Markets Play Defense

March 6, 2025 | etftrends.com

Time for Defensive Sector ETFs?

February 27, 2025 | zacks.com

Healthcare best performing sector as market angst builds

February 25, 2025 | marketwatch.com

Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.

February 25, 2025 | msn.com

Health Care Has Been a Top Sector

February 22, 2025 | finance.yahoo.com

What Top-Performing Healthcare Funds Are Buying Now

February 19, 2025 | msn.com

Final Trade: FWONK, XLV, MSFT, PEP

February 13, 2025 | youtube.com

18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard

February 8, 2025 | msn.com

Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025

February 7, 2025 | seekingalpha.com

Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)

February 6, 2025 | seeitmarket.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

February 4, 2025 | zacks.com

Can Health Care ETFs Aid Your Portfolio?

February 3, 2025 | etftrends.com

S&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)

December 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Why Archer Aviation Stock Could Soar After Palantir Partnership
By Jeffrey Neal Johnson | March 20, 2025
View Why Archer Aviation Stock Could Soar After Palantir Partnership
3 Energy Stocks With Cheap Valuations and Big Returns Ahead
By Sarah Horvath | March 19, 2025
View 3 Energy Stocks With Cheap Valuations and Big Returns Ahead
Intel Stock Surges on New CEO – The Real Story Runs Deeper
By Gabriel Osorio-Mazilli | March 13, 2025
View Intel Stock Surges on New CEO – The Real Story Runs Deeper
4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
By Thomas Hughes | March 7, 2025
View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?

PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Company Descriptions

AstraZeneca NASDAQ:AZN

$73.50 -0.29 (-0.39%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$73.63 +0.13 (+0.18%)

As of 07:36 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CME Group NASDAQ:CME

$265.29 +3.07 (+1.17%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$264.09 -1.20 (-0.45%)

As of 07:17 AM Eastern

CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. The company was founded in 1898 and is headquartered in Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$825.42 +2.91 (+0.35%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$821.66 -3.76 (-0.46%)

As of 07:32 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Morgan Stanley NYSE:MS

$116.84 +1.52 (+1.31%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$115.84 -1.01 (-0.86%)

As of 07:27 AM Eastern

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.

NVIDIA NASDAQ:NVDA

$108.38 -1.29 (-1.18%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$108.49 +0.11 (+0.10%)

As of 07:37 AM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Pfizer NYSE:PFE

$25.36 +0.15 (+0.58%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$25.26 -0.09 (-0.37%)

As of 07:34 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Wells Fargo & Company NYSE:WFC

$71.84 +1.16 (+1.63%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$71.36 -0.48 (-0.67%)

As of 07:31 AM Eastern

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Consumer Staples Select Sector SPDR Fund NYSEARCA:XLP

$81.67 +1.26 (+1.57%)

Closing price 03/31/2025 04:10 PM Eastern

Extended Trading

$81.47 -0.20 (-0.24%)

As of 07:35 AM Eastern

Consumer Staples Select Sector SPDR Fund (the Fund) seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in The Consumer Staples Select Sector Index (the Index).The Fund typically invests in substantially all of the securities represented in the Index in approximately the same proportions as the Index. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities consisting of the Index. In addition, the Fund may invest in cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by SSgA Funds Management, Inc. (SSgA FM). It invests in industries, such as food & staples retailing, household products, food products, tobacco, beverages and personal products. SSgA FM serves as the investment adviser to the Fund.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$146.01 +1.49 (+1.03%)

Closing price 03/31/2025 04:10 PM Eastern

Extended Trading

$145.26 -0.75 (-0.52%)

As of 07:33 AM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Earnings

Compare Dividends

Latest PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, AZN, LLY, CME, MS, WFC, XLP, XLV, and NVDA Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools